- Home
- ESLA
as of 08-26-2026 4:00pm EST
Estrella Immunopharma Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing CD19 and CD22-targeted ARTEMIS T-cell therapies with the capacity to address treatment challenges for patients with blood cancers and solid tumors.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | EMERYVILLE |
| Market Cap: | 32.0M | IPO Year: | 2021 |
| Target Price: | $8.00 | AVG Volume (30 days): | 23.6K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 1 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | annual |
| EPS: | -0.11 | EPS Growth: | -29.63 |
| 52 Week Low/High: | $0.68 - $3.15 | Next Earning Date: | 05-26-2026 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
| P/E Ratio: | -6.66 | Index: | N/A |
| Free Cash Flow: | N/A | FCF Growth: | N/A |
Compare ESLA vs Leading Stocks
See how ESLA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ESLA Estrella Immunopharma Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.